A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
- Sponsor:
- AbbVie, Inc
- Sponsor Study ID:
- M22-003
- CTO #:
- 103958
- NCT Number:
- NCT06191744
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Non-Hodgkin Lymphoma
- Study Objectives:
- To assess the efficacy of ER2 compared to CIT in subjects with previously untreated FL. The hypothesis corresponding to the primary objective is that ER2 will improve the CR rate at Month 30 (CR30)/120 weeks when compared to standard of care CIT.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Hess, Brian, at hessbr@musc.edu
- Study Coordinator, Mendiola, Hannah, at mendiola@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina